The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)

Jana Skřičková,Zdeněk Bortlíček,Karel Hejduk,Milos Pesek,Petr Zatloukal,Vitezslav Kolek,František Salajka,Leona Koubková,H. Čoupková,Milada Zemanová

The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients (pts)

2012

Jana Skřičková
Zdeněk Bortlíček
Karel Hejduk
Milos Pesek
Petr Zatloukal
Vitezslav Kolek
František Salajka
Leona Koubková
H. Čoupková
Milada Zemanová

This analysis, The Czech Republic experience with erlotinib in the treatment of a non-selected non-small cell lung cancer (NSCLC) population of 2365 patients, presented examines data obtained from the Czech population of NSCLC pts who received erlotinib.

Keywords:

non-small cell lung cancer (NSCLC)
Erlotinib
Czech
Lung cancer
Internal medicine
Medicine
Oncology
Population
non small cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations